The Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated that transcatheter aortic valve replacement (TAVR) for high-risk patients with aortic stenosis resulted in similar outcomes at 1, 2 and 3 years compared with surgical aortic valve replacement (SAVR). The present study reports the 5-year outcomes of this trial. The study enrolled 699 patients who were […]
Clinical Outcomes at 1 Year Following Transcatheter Aortic Valve Replacement
To date, long-term outcome data following transcatheter aortic valve replacement (TAVR) has only been available from clinical trial data. Evaluating long-term outcomes of TAVR in real-world use is important to ensure the anticipated benefits are observed in routine clinical practice. Using data from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve therapies […]
Transcatheter aortic valve implantation – are we moving from equivalent to preferred in high-risk surgical patients?
Transcatheter aortic valve implantation (TAVI) has expanded the options for the treatment of severe aortic stenosis, particularly in patients for whom the surgical risk of valve replacement is felt to be prohibitive. Prior studies have demonstrated TAVI reduces mortality relative to medical management among patients unable to undergo valve surgery. Among patients considered to be […]
2-year PARTNER data published
While the last 5 years have seen an incredible expansion in the use of transcatheter aortic-vlave replacement (TAVR) for patients with severe aortic stenosis who are not considered suitable for surgery, long-term outcomes data remain scant. The randomised Placement of Aortic Transcatheter Valves (PARTNER) trial found that, as compared with standard therapy, TAVR reduced symptoms […]